Eleven Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 7

Eleven Therapeutics General Information

Description

Developer of an extended durability mRNA therapeutics designed to transform ribonucleic acid drug development into a programmable processor. The company's pipeline is dedicated to tackling unmet medical needs in the realms of metabolic, endocrinologic, and infectious diseases by the utilization of proprietary high-throughput AI-enabled screening platforms, strategically employed to enhance the stability and facilitate their targeted and selective delivery, enabling scientists to have fully programmable ribonucleic acid molecules with superior durability and specificity.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • CRUK Cambridge Institute
  • Robinson Way
  • Cambridge CB2 0RE
  • England, United Kingdom
Primary Industry
Biotechnology
Corporate Office
  • CRUK Cambridge Institute
  • Robinson Way
  • Cambridge CB2 0RE
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eleven Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator Completed Generating Revenue
4. Seed Round 02-Aug-2022 Completed Generating Revenue
3. Grant 18-Dec-2021 Completed Generating Revenue
2. Grant 01-Jun-2021 $3.9M Completed Generating Revenue
1. Seed Round 01-Apr-2021 Completed Startup
To view Eleven Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eleven Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an extended durability mRNA therapeutics designed to transform ribonucleic acid drug development into a pro
Biotechnology
Cambridge, United Kingdom
31 As of 2025

Beijing, China
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eleven Therapeutics Competitors (3)

One of Eleven Therapeutics’s 3 competitors is FibroGen (China), a Corporate Backed or Acquired company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
FibroGen (China) Corporate Backed or Acquired Beijing, China
Avalyn Pharma Formerly VC-backed Boston, MA
Kyntra Bio Formerly VC-backed San Francisco, CA
You’re viewing 3 of 3 competitors. Get the full list »

Eleven Therapeutics Patents

Eleven Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025141025-A2 Novel capping strategies for mrna 5'cap Inactive 26-Dec-2023
WO-2025141025-A3 Novel capping strategies for mrna 5'cap Inactive 26-Dec-2023
EP-4746924-A1 Non-natural building blocks for enhanced translation and stability of mrna Pending 17-Jul-2023
WO-2025017029-A1 Non-natural building blocks for enhanced translation and stability of mrna Inactive 17-Jul-2023
WO-2024261215-A1 High throughput screens of translation and stability of mrna using barcoded xrna display and its variations Inactive 22-Jun-2023 C12N15/1062
To view Eleven Therapeutics’s complete patent history, request access »

Eleven Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eleven Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innovate UK Government Minority
Gates Foundation Not-For-Profit Venture Capital
Entrée Capital Venture Capital Minority
Kindred Capital Venture Capital Minority
NFX Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Eleven Therapeutics FAQs

  • When was Eleven Therapeutics founded?

    Eleven Therapeutics was founded in 2020.

  • Where is Eleven Therapeutics headquartered?

    Eleven Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of Eleven Therapeutics?

    Eleven Therapeutics has 31 total employees.

  • What industry is Eleven Therapeutics in?

    Eleven Therapeutics’s primary industry is Biotechnology.

  • Is Eleven Therapeutics a private or public company?

    Eleven Therapeutics is a Private company.

  • What is Eleven Therapeutics’s current revenue?

    The current revenue for Eleven Therapeutics is .

  • How much funding has Eleven Therapeutics raised over time?

    Eleven Therapeutics has raised $22M.

  • Who are Eleven Therapeutics’s investors?

    Innovate UK, Gates Foundation, Entrée Capital, Kindred Capital, and NFX are 5 of 7 investors who have invested in Eleven Therapeutics.

  • Who are Eleven Therapeutics’s competitors?

    FibroGen (China), Avalyn Pharma, and Kyntra Bio are competitors of Eleven Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process